Neuronal Cholesterol Deficiency Mediated by Astrocytic SREBP2 Downregulation Leads to Postoperative Cognitive Dysfunction Through Impairment of Hippocampal Synaptic Plasticity and Excitatory Synaptic Transmission
Brief intro:
- Author: He Huang, Chenrui Zhou, Chen Chen, Huimei Tang, Wei Dong, Jie Wan, Weiye Kang, Ao Sun, Yiqi Liu, Chunhui Jin, Xiaobin Lyu, Yankun Zhu, Chenghua Zhou, Yuqing Wu
- Journal: Advanced Science
- Doi: https://www.doi.org/10.1002/advs.202519874Digital Object Identifier (DOI)
- Publication Date: 2026/2/12
Abstract
Postoperative cognitive dysfunction (POCD) negatively impacts prognosis; however, the underlying mechanisms remain unclear. We demonstrated that tibial fracture surgery led to cognitive dysfunction in 18-month-old mice, concomitant with a reduction in hippocampal levels of cholesterol and its key metabolite 24-hydroxycholesterol (24-OHC). Clinically, reduced blood 24-OHC levels were associated with cognitive decline in elderly surgery patients. Mechanistically, downregulation of sterol regulatory element-binding protein 2 (SREBP2) in reactive astrocytes of the hippocampal dorsal CA1 (dCA1) region was an important cause of postoperative cholesterol deficiency, which in turn impaired synaptic plasticity and excitatory synaptic transmission; furthermore, this deficit could be rescued by direct cholesterol replenishment in the dCA1. Importantly, we established multiple effective therapeutic strategies—astrocyte-specific SREBP2 overexpression, chemogenetic suppression of reactive astrocytes, and minocycline administration—all of which effectively reversed surgery-induced cholesterol loss, alleviated synaptic dysfunction, and ultimately improved cognitive performance. Taken together, our findings not only position astrocytic SREBP2 as a promising therapeutic target for POCD but also highlight the potential diagnostic value of monitoring brain cholesterol metabolism, though this requires validation in larger longitudinal cohorts.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.